Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer

Makito Miyake, Kokichi Sugano, Hitomi Sugino, Kazuho Imai, Eri Matsumoto, Koshi Maeda, Shinich Fukuzono, Hiroki Ichikawa, Kiyotaka Kawashima, Kaoru Hirabayashi, Tetsuro Kodama, Hiroyuki Fujimoto, Tadao Kakizoe, Yae Kanai, Kiyohide Fujimoto, Yoshihiko Hirao

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The fibroblast growth factor receptor (FGFR)-3 gene encodes a receptor tyrosine kinase that is frequently mutated in non-muscle invasive bladder cancer (NMIBC). A sensitive and quantitative assay using peptide nucleic acid-mediated real-time PCR was developed for detecting FGFR3 mutations in the urine samples and evaluated as a molecular marker for detecting intravesical recurrence of NMIBC in patients undergoing transurethral resection of bladder tumor. FGFR3 mutation was examined in tumor tissues and serially taken pre- and postoperative urine sediments in 45 NMIBC patients with a median follow up of 32 months. FGFR3 mutations were detected in 53.3% (24/45) of primary tumor tissues, among which intravesical recurrence developed in 37.5% (9/24) of cases. FGFR3 mutation in the primary tumor was not a significant prognostic indicator for recurrence, while the proportion of FGFR3 mutation (i.e. tumor cellularity was ≥11%) in the preoperative urine sediments was a significant indicator for recurrence in patients with FGFR3 mutations in the primary tumors. FGFR3 mutations were detected in 78% (7/9) of postoperative urine samples from recurrent cases with FGFR3 mutations in the tumor, while no mutations were detected in the urine of 15 non-recurrent cases. Urine cytology was negative in all cases with FGFR3 mutations in the primary tumors, while the sensitivity of cytological examination was as high as 56% (5/9) in cases showing wild-type FGFR3 in the primary tumors. Urine FGFR3 mutation assay and cytological examination may be available in the future as complementary diagnostic modalities in postoperative management of NMIBC.

Original languageEnglish
Pages (from-to)250-258
Number of pages9
JournalCancer Science
Volume101
Issue number1
DOIs
Publication statusPublished - 2010 Jan
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Urinary Bladder Neoplasms
Urine
Recurrence
Mutation
Neoplasms
Peptide Nucleic Acids
Receptor Protein-Tyrosine Kinases
Cell Biology
Real-Time Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. / Miyake, Makito; Sugano, Kokichi; Sugino, Hitomi; Imai, Kazuho; Matsumoto, Eri; Maeda, Koshi; Fukuzono, Shinich; Ichikawa, Hiroki; Kawashima, Kiyotaka; Hirabayashi, Kaoru; Kodama, Tetsuro; Fujimoto, Hiroyuki; Kakizoe, Tadao; Kanai, Yae; Fujimoto, Kiyohide; Hirao, Yoshihiko.

In: Cancer Science, Vol. 101, No. 1, 01.2010, p. 250-258.

Research output: Contribution to journalArticle

Miyake, M, Sugano, K, Sugino, H, Imai, K, Matsumoto, E, Maeda, K, Fukuzono, S, Ichikawa, H, Kawashima, K, Hirabayashi, K, Kodama, T, Fujimoto, H, Kakizoe, T, Kanai, Y, Fujimoto, K & Hirao, Y 2010, 'Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer', Cancer Science, vol. 101, no. 1, pp. 250-258. https://doi.org/10.1111/j.1349-7006.2009.01334.x
Miyake, Makito ; Sugano, Kokichi ; Sugino, Hitomi ; Imai, Kazuho ; Matsumoto, Eri ; Maeda, Koshi ; Fukuzono, Shinich ; Ichikawa, Hiroki ; Kawashima, Kiyotaka ; Hirabayashi, Kaoru ; Kodama, Tetsuro ; Fujimoto, Hiroyuki ; Kakizoe, Tadao ; Kanai, Yae ; Fujimoto, Kiyohide ; Hirao, Yoshihiko. / Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. In: Cancer Science. 2010 ; Vol. 101, No. 1. pp. 250-258.
@article{fb66e7aa5a894513998e5f94b4d8949e,
title = "Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer",
abstract = "The fibroblast growth factor receptor (FGFR)-3 gene encodes a receptor tyrosine kinase that is frequently mutated in non-muscle invasive bladder cancer (NMIBC). A sensitive and quantitative assay using peptide nucleic acid-mediated real-time PCR was developed for detecting FGFR3 mutations in the urine samples and evaluated as a molecular marker for detecting intravesical recurrence of NMIBC in patients undergoing transurethral resection of bladder tumor. FGFR3 mutation was examined in tumor tissues and serially taken pre- and postoperative urine sediments in 45 NMIBC patients with a median follow up of 32 months. FGFR3 mutations were detected in 53.3{\%} (24/45) of primary tumor tissues, among which intravesical recurrence developed in 37.5{\%} (9/24) of cases. FGFR3 mutation in the primary tumor was not a significant prognostic indicator for recurrence, while the proportion of FGFR3 mutation (i.e. tumor cellularity was ≥11{\%}) in the preoperative urine sediments was a significant indicator for recurrence in patients with FGFR3 mutations in the primary tumors. FGFR3 mutations were detected in 78{\%} (7/9) of postoperative urine samples from recurrent cases with FGFR3 mutations in the tumor, while no mutations were detected in the urine of 15 non-recurrent cases. Urine cytology was negative in all cases with FGFR3 mutations in the primary tumors, while the sensitivity of cytological examination was as high as 56{\%} (5/9) in cases showing wild-type FGFR3 in the primary tumors. Urine FGFR3 mutation assay and cytological examination may be available in the future as complementary diagnostic modalities in postoperative management of NMIBC.",
author = "Makito Miyake and Kokichi Sugano and Hitomi Sugino and Kazuho Imai and Eri Matsumoto and Koshi Maeda and Shinich Fukuzono and Hiroki Ichikawa and Kiyotaka Kawashima and Kaoru Hirabayashi and Tetsuro Kodama and Hiroyuki Fujimoto and Tadao Kakizoe and Yae Kanai and Kiyohide Fujimoto and Yoshihiko Hirao",
year = "2010",
month = "1",
doi = "10.1111/j.1349-7006.2009.01334.x",
language = "English",
volume = "101",
pages = "250--258",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer

AU - Miyake, Makito

AU - Sugano, Kokichi

AU - Sugino, Hitomi

AU - Imai, Kazuho

AU - Matsumoto, Eri

AU - Maeda, Koshi

AU - Fukuzono, Shinich

AU - Ichikawa, Hiroki

AU - Kawashima, Kiyotaka

AU - Hirabayashi, Kaoru

AU - Kodama, Tetsuro

AU - Fujimoto, Hiroyuki

AU - Kakizoe, Tadao

AU - Kanai, Yae

AU - Fujimoto, Kiyohide

AU - Hirao, Yoshihiko

PY - 2010/1

Y1 - 2010/1

N2 - The fibroblast growth factor receptor (FGFR)-3 gene encodes a receptor tyrosine kinase that is frequently mutated in non-muscle invasive bladder cancer (NMIBC). A sensitive and quantitative assay using peptide nucleic acid-mediated real-time PCR was developed for detecting FGFR3 mutations in the urine samples and evaluated as a molecular marker for detecting intravesical recurrence of NMIBC in patients undergoing transurethral resection of bladder tumor. FGFR3 mutation was examined in tumor tissues and serially taken pre- and postoperative urine sediments in 45 NMIBC patients with a median follow up of 32 months. FGFR3 mutations were detected in 53.3% (24/45) of primary tumor tissues, among which intravesical recurrence developed in 37.5% (9/24) of cases. FGFR3 mutation in the primary tumor was not a significant prognostic indicator for recurrence, while the proportion of FGFR3 mutation (i.e. tumor cellularity was ≥11%) in the preoperative urine sediments was a significant indicator for recurrence in patients with FGFR3 mutations in the primary tumors. FGFR3 mutations were detected in 78% (7/9) of postoperative urine samples from recurrent cases with FGFR3 mutations in the tumor, while no mutations were detected in the urine of 15 non-recurrent cases. Urine cytology was negative in all cases with FGFR3 mutations in the primary tumors, while the sensitivity of cytological examination was as high as 56% (5/9) in cases showing wild-type FGFR3 in the primary tumors. Urine FGFR3 mutation assay and cytological examination may be available in the future as complementary diagnostic modalities in postoperative management of NMIBC.

AB - The fibroblast growth factor receptor (FGFR)-3 gene encodes a receptor tyrosine kinase that is frequently mutated in non-muscle invasive bladder cancer (NMIBC). A sensitive and quantitative assay using peptide nucleic acid-mediated real-time PCR was developed for detecting FGFR3 mutations in the urine samples and evaluated as a molecular marker for detecting intravesical recurrence of NMIBC in patients undergoing transurethral resection of bladder tumor. FGFR3 mutation was examined in tumor tissues and serially taken pre- and postoperative urine sediments in 45 NMIBC patients with a median follow up of 32 months. FGFR3 mutations were detected in 53.3% (24/45) of primary tumor tissues, among which intravesical recurrence developed in 37.5% (9/24) of cases. FGFR3 mutation in the primary tumor was not a significant prognostic indicator for recurrence, while the proportion of FGFR3 mutation (i.e. tumor cellularity was ≥11%) in the preoperative urine sediments was a significant indicator for recurrence in patients with FGFR3 mutations in the primary tumors. FGFR3 mutations were detected in 78% (7/9) of postoperative urine samples from recurrent cases with FGFR3 mutations in the tumor, while no mutations were detected in the urine of 15 non-recurrent cases. Urine cytology was negative in all cases with FGFR3 mutations in the primary tumors, while the sensitivity of cytological examination was as high as 56% (5/9) in cases showing wild-type FGFR3 in the primary tumors. Urine FGFR3 mutation assay and cytological examination may be available in the future as complementary diagnostic modalities in postoperative management of NMIBC.

UR - http://www.scopus.com/inward/record.url?scp=71849086230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849086230&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01334.x

DO - 10.1111/j.1349-7006.2009.01334.x

M3 - Article

C2 - 19843069

AN - SCOPUS:71849086230

VL - 101

SP - 250

EP - 258

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -